A new trading day began on Friday, with Esperion Therapeutics Inc (NASDAQ: ESPR) stock price up 13.79% from the previous day of trading, before settling in for the closing price of $2.9. ESPR’s price has ranged from $0.69 to $3.94 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 40.11% over the past five years. Meanwhile, its annual earnings per share averaged 69.41%. With a float of $196.99 million, this company’s outstanding shares have now reached $200.16 million.
Esperion Therapeutics Inc (ESPR) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Esperion Therapeutics Inc is 2.30%, while institutional ownership is 48.90%. The most recent insider transaction that took place on Sep 17 ’25, was worth 17,573. In this transaction General Counsel of this company sold 6,267 shares at a rate of $2.80, taking the stock ownership to the 393,670 shares. Before that another transaction happened on Sep 17 ’25, when Company’s President and CEO sold 28,427 for $2.79, making the entire transaction worth $79,254. This insider now owns 1,518,831 shares in total.
Esperion Therapeutics Inc (ESPR) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.15 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.41% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Here are Esperion Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.53, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach -0.03 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (NASDAQ: ESPR) saw its 5-day average volume 9.0 million, a positive change from its year-to-date volume of 5.16 million. As of the previous 9 days, the stock’s Stochastic %D was 91.00%.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 97.20%, which indicates a significant increase from 92.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was higher than the 0.13 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.25, while its 200-day Moving Average is $1.65. Nevertheless, the first resistance level for the watch stands at $3.46 in the near term. At $3.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.87. If the price goes on to break the first support level at $3.06, it is likely to go to the next support level at $2.81. Assuming the price breaks the second support level, the third support level stands at $2.65.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
With a market capitalization of 665.36 million, the company has a total of 201,623K Shares Outstanding. Currently, annual sales are 332,310 K while annual income is -51,750 K. The company’s previous quarter sales were 82,390 K while its latest quarter income was -12,720 K.
